A Study Assessing KB707 for Lung Cancer Treatment
Phase 1/2
250
about 4.3 years
18+
14 sites in AL, AZ, CA +8
What this study is about
This trial is testing a new treatment called KB707 in people with advanced lung cancer. The goal is to see if KB707 can help the body fight the cancer and how safe it is. This is a Phase 1/2 trial, meaning it's exploring both safety and early effectiveness.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive KB707
- 2.Take Chemotherapy
- 3.Take Docetaxel
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
docetaxel, immunotherapy (PD-1 inhibitor immunotherapy (pembrolizumab)), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: To evaluate the safety and tolerability of inhaled KB707 based upon assessment of adverse events (AE)
Secondary: To evaluate the preliminary efficacy of inhaled KB707 as determined by overall response rate (ORR), To evaluate whether the proposed dose ranges include the maximum tolerated dose of KB707 as determined by incidence of dose limiting toxicities (DLTs)
Oncology